Scientific article
Review
English

Antiplatelet Therapy: Targeting the TxA2 Pathway

Published in

Journal of cardiovascular translational research, vol. 7, no. 1, p. 29-38

Publication date

2014

Abstract

The thromboxane (Tx) A2 pathway is a major contributor to the amplification of the initial platelet activation process. TxA2 mediates its effect through the thromboxane prostanoid (TP) receptor that is expressed not only in platelets, but also in endothelial cells, macrophages, and monocytes, and thus contributes to the development of atherosclerotic lesions. The TxA2 pathway is therefore a major target in the treatment of cardiovascular disease. Aspirin-the most widely used antiplatelet drug-is very effective at inhibiting platelet-derived TxA2 synthesis. However, aspirin's effects can be overcome by several other soluble agonists such as isoprostanes, which are aspirin-insensitive ligands of the TP receptor that are preferentially produced in diabetes mellitus. Other drugs, with either inhibitory effects on Tx synthase or antagonist effects on TP, have been developed with the hope of providing a better, more complete inhibition of the TxA2 pathway.

Citation (ISO format)

FONTANA, Pierre et al. Antiplatelet Therapy: Targeting the TxA2 Pathway. In: Journal of cardiovascular translational research, 2014, vol. 7, n° 1, p. 29–38. doi: 10.1007/s12265-013-9529-1

Main files (1)

Article (Published version)

Identifiers

Journal ISSN

1937-5387
667views
2downloads

Technical informations

Creation

14/03/2014 15:05:00

First validation

14/03/2014 15:05:00

Update

13/10/2025 22:56:57

Status update

03/02/2025 11:33:28

Last indexation

28/09/2026 12:17:10
All rights reserved by Archive ouverte UNIGE and the University of Geneva
OpenAIRE Indexed & Validated